Pharmacogenomics draft guidance
FDA is understood to be on track to release its pharmacogenomics draft guidance in August. The draft guidance is understood to state that FDA will not require sponsors to collect pharmacogenomics data for product applications (1"The Pink Sheet" April 14, 2003, p. 12). The Drug Information Association is planning a meeting on pharmacogenomics for November...
You may also be interested in...
The regulatory impact of different categories of pharmacogenomic data will be addressed in a draft guidance, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said at FDA's Science Board Advisory Committee meeting April 9
The OTC Marketing Awards 2021 will now take place on 1 December, with entries invited from activity in 2020 and 2021. A special award – Best COVID-19 initiative by an OTC Company – will also recognize the efforts made by the British consumer healthcare industry during the COVID-19 pandemic.
The Dublin-based drugmaker, powered by climbing revenues of Lojuxta and Myalept, is preparing its launch teams for Filsuvez, which has the potential to become the first treatment approved for epidermolysis bullosa and the company is banking on speedy regulatory reviews.